（文章来源：证券日报） 证券日报网讯 2月9日，中国宝安在互动平台回答投资者提问时表示，截至2026年1月30日，公司股东总 户数约为14.99万户。 ...

证券日报网讯2月9日，中国宝安（000009）在互动平台回答投资者提问时表示，目前公司合计持有 746591901股贝特瑞股份。 ...

证券日报网讯2月9日，中国宝安（000009）在互动平台回答投资者提问时表示，公司存货、应收款上升 主要是由于行业经营特点及业务规模发展所致，公司按会计准则计提坏账准备。公司后续将进一步强化 应收款项管理，严控坏账风险，切实维护公司及股东利益。 ...

证券日报网讯2月9日，中国宝安（000009）在互动平台回答投资者提问时表示，国际精密线性伺服执行 器目前处于研发迭代阶段，产品还未成熟。 ...

（文章来源：证券日报） 证券日报网讯 2月9日，中国宝安在互动平台回答投资者提问时表示，截至2026年1月20日，公司股东总 户数约为14.80万户。 ...

证券日报网讯 2月9日，中国宝安在互动平台回答投资者提问时表示，公司依规开展投资者问题回复工 作。 （文章来源：证券日报） ...

Group 1 - XianDao Intelligent has set the final price for its H-share public offering at HKD 45.8 per share, with expected listing on February 11, 2026 [1] - Jida Communication is a candidate for a project with China Mobile, with an estimated service fee of approximately CNY 51.04 million [2] - Bowei Alloy's controlling shareholder plans to increase holdings by CNY 100 million to 150 million from February 10 to August 9, 2026 [3] Group 2 - Xiamen Airport reported 16,368 aircraft takeoffs and landings in January 2026, a year-on-year decrease of 4.82%, with passenger throughput of 2.38 million, down 3.84% [4] - Yitong Century has won a bid for a project worth CNY 107 million, providing comprehensive maintenance services for China Tower [5] - Huayi Brothers' controlling shareholder's 70 million shares are subject to judicial auction, representing 42.89% of his holdings and 2.52% of the company's total shares [6] Group 3 - Lianhuan Pharmaceutical received approval for the sale of Tadalafil tablets (20mg) in Ghana [7] - Aonong Biological reported a pig sales volume of 166,600 in January 2026, a year-on-year increase of 35.36% [8] - Xiantan Co. achieved chicken product sales revenue of CNY 546 million in January 2026, a year-on-year increase of 54.9% [9] Group 4 - Zhengbang Technology reported a January sales revenue of CNY 816 million from pig sales, a year-on-year increase of 19.69% [10] - Qianjin Pharmaceutical's net profit for 2025 grew by 24.74% to CNY 288 million [11] - Xinhua Pharmaceutical received a drug registration certificate for glucosamine sulfate capsules [12] Group 5 - Yuandong Bio completed the first dosing of its EP-0210 monoclonal antibody in a Phase I clinical trial for inflammatory bowel disease [13] - Jiaokong Technology signed a contract for the Sydney Metro West Line signal system subcontracting project worth AUD 93.53 million [14] - Dangsheng Technology signed a strategic cooperation framework agreement with Huineng Technology in solid-state batteries and the new energy industry [15] Group 6 - Jinhui Co. plans to acquire 100% of Fusheng Mining for CNY 210 million [16] - Cangzhou Mingzhu announced Guangzhou Light Industry as its new controlling shareholder after a share transfer [17] - Dingxin Technology's vice president was fined CNY 120,000 for short-term trading [18][19] Group 7 - China Modern Pharmaceutical's subsidiary passed a GMP compliance inspection for its production line [20] - Chaosheng Electronics plans to increase capital by CNY 400 million in its subsidiary to enhance competitiveness [21] - Lonyu Mountain reported a 25.03% year-on-year increase in pig sales revenue in January 2026 [22] Group 8 - Sanbo Brain Science's chairman has been released from investigation, and the company is operating normally [23] - Hainan Mining is planning to acquire control of Luoyang Fengrui Fluorine Industry and will resume trading on February 10, 2026 [24] - Dongwei Technology's net profit for 2025 increased by 86.81% [25] Group 9 - Yuanjie Technology plans to invest CNY 1.251 billion in a semiconductor chip and device R&D production base [26] - Metro Design signed a contract for an energy management project with Guangzhou Metro Group worth CNY 924 million [27] - Zhongmin Energy intends to acquire 51% of Fujian Yongtai Mintou Pumped Storage Co. for CNY 864 million [28] Group 10 - Dianzhi Technology plans to repurchase shares worth CNY 100 million to 200 million [29] - China Baoan was not selected as a restructuring investor for the Singshan Group [30] - Zhiguang Electric's subsidiary signed a CNY 1.004 billion contract for energy storage systems [31] Group 11 - Zhifei Biological received approval for a clinical trial of its herpes zoster vaccine [32] - KQ Bio received a new veterinary drug registration certificate for a vaccine against porcine circovirus type 2 [33] - Huanxu Electronics reported a 4% year-on-year increase in consolidated revenue for January 2026 [34] Group 12 - Xiangjia Co. reported a 10.42% year-on-year increase in live poultry sales revenue in January 2026 [35] - Kemin Foods' subsidiary reported a 68.29% year-on-year increase in pig sales revenue in January 2026 [36] - Liyuan Technology signed a procurement contract worth CNY 54.98 million [37] Group 13 - Jiuqiang Bio received a medical device registration certificate for a fibrin degradation product detection kit [38] - Zhongguancun's subsidiary passed the consistency evaluation for Tramadol Hydrochloride tablets [39] - Rundou Co. received a drug registration certificate for Candesartan Etil [40]

格隆汇2月9日丨中国宝安(000009.SZ)公布，根据宁波杉杉股份（维权）有限公司于2026年2月9日披露 的《宁波杉杉股份有限公司关于控股股东及其子公司签署重整投资协议的公告》（公告编号：2026- 004），公司及所牵头的联合体未中选成为杉杉集团及其全资子公司宁波朋泽实质合并重整的重整投资 人。根据杉杉集团和宁波朋泽合并重整案管理人之文件规定，杉杉集团和宁波朋泽合并重整案管理人将 退返公司前期缴纳的尽调保证金。 ...

格隆汇2月9日丨中国宝安(000009.SZ)公布，根据宁波杉杉股份（维权）有限公司于2026年2月9日披露 的《宁波杉杉股份有限公司关于控股股东及其子公司签署重整投资协议的公告》（公告编号：2026- 004），公司及所牵头的联合体未中选成为杉杉集团及其全资子公司宁波朋泽实质合并重整的重整投资 人。根据杉杉集团和宁波朋泽合并重整案管理人之文件规定，杉杉集团和宁波朋泽合并重整案管理人将 退返公司前期缴纳的尽调保证金。 ...

关于参与杉杉集团及其全资子公司实质合并 重整投资人招募的进展公告 证券代码：000009 证券简称：中国宝安 公告编号：2026-001 中国宝安集团股份有限公司 敬请投资者理性投资，注意投资风险。 特此公告 中国宝安集团股份有限公司董事局 二〇二六年二月十日 1 本公司及董事局全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏。 中国宝安集团股份有限公司（以下简称"公司"）于 2025 年 12 月 13 日披 露了《关于参与杉杉集团及其全资子公司实质合并重整投资人招募的公告》（公 告编号：2025-044），公司作为重整投资联合体（以下简称"联合体"）牵头人， 联合下属子公司贝特瑞新材料集团股份有限公司及其他潜在投资人参与杉杉集 团有限公司（以下简称"杉杉集团"）及其全资子公司宁波朋泽贸易有限公司（以 下简称"宁波朋泽"）的实质合并重整投资人招募。 根据宁波杉杉股份有限公司于 2026 年 2 月 9 日披露的《宁波杉杉股份有限 公司关于控股股东及其子公司签署重整投资协议的公告》（公告编号：2026-004）， 公司及所牵头的联合体未中选成为杉杉集团及其全资子公司宁波朋泽实 ...